Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pro-Teico study of teicoplanin prophylaxis in pediatric acute myeloid leukemia
2023-506546-23-00Phase 3Authorised
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of teicoplanin in acute myeloid leukemia (AML) (3 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Dose-limiting toxicities in safety run-in, First viridans group streptococcal bloodstream infection and 1 more. Planned start May 2020; status: authorised.
02
Drugs
teicoplanin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-506546-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506546-23-00.